| Property | Value |
|---|
|
?:abstract
|
-
INTRODUCTION Adipose-derived stromal cells (ADSCs) can be an important alternative in COVID 19 prevention, treatment and subsequent sequelae repair. However, ACE-2 plays a common role in the pathogenesis of adipocyte hypertrophy and COVID 19. Areas covered: In this \'Perspective\', the author would like to emphasize the use of adipose tissue-derived stromal cells in COVID 19 and the issues that clinicians should pay attention to in fat graft applications in terms of adipose tissue-RAS relationship. The new normal for adipose tissue in COVID 19 will be highlighted. Expert Opinion: ADSCs may potentially be used in COVID-19. However, it has been speculated that ACE2 receptors are responsible for the pathogenesis of adipose tissue overgrowth and may be a potential danger in terms of the relationship between ACE2 receptors and COVID19. We speculate that reducing the size of overgrown fat tissue by ultra-sharp blades and using near-normal adipocytes will create a \'new normal\'.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1080/14712598.2020.1822812
|
|
?:journal
|
-
Expert_opinion_on_biological_therapy
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
New Normal: Two aspects of adipose tissue in COVID19 - Treat and threat?
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}